Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Isotechnika Pharma Inc IPHAF

GREY:IPHAF - Post Discussion

Isotechnika Pharma Inc > New Company
View:
Post by Investandpray on Feb 06, 2013 12:20am

New Company

There is no website for Aurinia Pharma? This is hard to get a feeling of what this new company will look like or calculate it's new worth? Aurinia Pharma has been conducting lupus trials and is into a phase 2b this year. They must be getting funding from somewhere? 

One can only pray this is going to work out? I sure will be. GLTA even you isaloser.

Comment by klank37 on Feb 06, 2013 9:01am
I AGREE COULD NOT FIND A SINGLE THING ABOUT THEM. PLEASE CAN YOU TELL ME WHAT THAT EXACTLY MEAN.  The merger is expected to be effected by an exchange of Isotechnika shares for securities of Aurinia, resulting in a 60:40 post-merger ownership split between Isotechnika and Aurinia, respectively. I GUESS FAIRLY STRAIT FORWARD....BUT....DILUTION???? OR IT ONLY MEAN THAT ISA WILL OWN 60 %  ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities